148 related articles for article (PubMed ID: 36142655)
21. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women.
Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Cai H; Fair AM; Shu XO; Zheng W
Breast Cancer Res Treat; 2014 Jul; 146(2):439-46. PubMed ID: 24986698
[TBL] [Abstract][Full Text] [Related]
22. Body weight management in overweight and obese breast cancer survivors.
Shaikh H; Bradhurst P; Ma LX; Tan SYC; Egger SJ; Vardy JL
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012110. PubMed ID: 33305350
[TBL] [Abstract][Full Text] [Related]
23. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
Bowers LW; Maximo IX; Brenner AJ; Beeram M; Hursting SD; Price RS; Tekmal RR; Jolly CA; deGraffenried LA
Cancer Res; 2014 Aug; 74(16):4446-57. PubMed ID: 25125682
[TBL] [Abstract][Full Text] [Related]
24. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
25. Obesity-associated Breast Cancer: Analysis of risk factors.
Engin A
Adv Exp Med Biol; 2017; 960():571-606. PubMed ID: 28585217
[TBL] [Abstract][Full Text] [Related]
26. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Morris PG; Hudis CA; Giri D; Morrow M; Falcone DJ; Zhou XK; Du B; Brogi E; Crawford CB; Kopelovich L; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2011 Jul; 4(7):1021-9. PubMed ID: 21622727
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
29. Obesity, mammography use and accuracy, and advanced breast cancer risk.
Kerlikowske K; Walker R; Miglioretti DL; Desai A; Ballard-Barbash R; Buist DS
J Natl Cancer Inst; 2008 Dec; 100(23):1724-33. PubMed ID: 19033562
[TBL] [Abstract][Full Text] [Related]
30. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
31. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
32. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
33. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
[TBL] [Abstract][Full Text] [Related]
34. Dietary Carbohydrate, Glycemic Index, Glycemic Load, and Breast Cancer Risk Among Mexican Women.
Amadou A; Degoul J; Hainaut P; Chajes V; Biessy C; Torres Mejia G; Huybrechts I; Moreno Macia H; Ortega C; Angeles-Llerenas A; Romieu I
Epidemiology; 2015 Nov; 26(6):917-24. PubMed ID: 26340313
[TBL] [Abstract][Full Text] [Related]
35. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
36. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
37. Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
Noh H; Charvat H; Freisling H; Ólafsdóttir GH; Ólafsdóttir EJ; Tryggvadóttir L; Arnold M; Soerjomataram I
Int J Cancer; 2020 Aug; 147(3):793-802. PubMed ID: 31755107
[TBL] [Abstract][Full Text] [Related]
38. Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer.
Warren LE; Ligibel JA; Chen YH; Truong L; Catalano PJ; Bellon JR
Ann Surg Oncol; 2016 Nov; 23(12):3870-3879. PubMed ID: 27448118
[TBL] [Abstract][Full Text] [Related]
39. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
